NCT07178067 (IMPACT-ALS) is a clinical trial of Mediterranean diet in Amyotrophic Lateral Sclerosis, sponsored by George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures.

What drugs are being tested in NCT07178067?

Interventions in NCT07178067: Mediterranean diet.

What condition does NCT07178067 study?

NCT07178067 studies Amyotrophic Lateral Sclerosis.

Is NCT07178067 still recruiting?

NCT07178067 is currently completed. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT07178067: IMPACT-ALS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Longitudinal Evaluation of Short-Chain Fatty Acid Profiles During the Natural Disease Course and a Mediterranean Diet Intervention in Amyotrophic Lateral Sclerosis Patients

Completed Last updated 17 September 2025

What this trial tests

trial testing Mediterranean diet in Amyotrophic Lateral Sclerosis in 44 participants. Completed in 30 November 2023.

Timeline

21 July 2022

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Status	Completed
Study type	OBSERVATIONAL
Enrollment	44
Start date	21 July 2022
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across Romania

Drugs / interventions tested

Mediterranean diet

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study explored the connection between the gut microbiota and the brain in patients with amyotrophic lateral sclerosis (ALS), specifically the modulation of short-chain fatty acids during disease progression and after following a Mediterranean diet for 6 months. Recent research suggests that the gut microbiome-the community of bacteria and other microorganisms living in our intestines-may influence how ALS develops and progresses. The hypothesis was that changes in the gut microbiome and the substances it produces, such as short-chain fatty acids (SCFAs), may play an important role in ALS progression. Additionally, the effect of the Mediterranean diet on circulating short-chain fatty acid concentrations was assessed.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Short-Chain Fatty Acid Profiles in Amyotrophic Lateral Sclerosis: Longitudinal Effects of Disease and Mediterranean Diet Intervention.
Moțățăianu A, Ion V, Dumitreasă M, Ormenișan I, et al · · 2025 · cited 1× · PMID 41154611 · DOI 10.3390/biom15101380
The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function.
Yang J, Song X, Yan S, Li Q, et al · · 2025 · PMID 41601624 · DOI 10.3389/fimmu.2025.1739329

Verify or expand the search:

Other trials of Mediterranean diet

Trials testing the same drug.

NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome · NA · recruiting
NCT07017127 — Remission of Type 2 Diabetes With Lifestyle Intervention · NA · recruiting
NCT07055620 — Effects of Different Dietary Models on Eating Behavior and Obesity Management in Overweight and Obese Individuals · NA · completed
NCT06774079 — Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients · Phase 4 · recruiting
NCT06765369 — How the Mediterranean Diet Affects You: Predicting Responses Based on Your Microbiome · NA · not yet recruiting

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures trials

Trials by the same sponsor.

NCT05261724 — Diffusion-tensor Imaging in Brain Tumors Evaluation · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07178067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07178067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing